Statistically Significant (p=0.006) Waist Circumference Reduction of 9.8 cm at Day 54 Significant Direct Hepatic Activity with a 23.7% Reduction in Liver Stiffness (VCTE) by Day 54 Strong Glycemic ...
SALT LAKE CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinical-stage ...
A century ago, two oddly domestic puzzles helped set the rules for what modern science treats as "real": a Guinness brewer charged with quality control and a British lady insisting she can taste ...
Chief Research Scientist, CSIRO Environment; Executive Director, Global Carbon Project, CSIRO Pep Canadell receives funding from the Australian National Environmental Science Program - Climate Systems ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ...
*The main analyses of ambulatory BP endpoints include patients with valid ambulatory blood pressure monitoring at both baseline and Week 12, without imputation of missing data. The Phase III Bax24 ...
Princess U. Ogbogu, Division Chief of Pediatric Allergy, Immunology, and Rheumatology at University Hospitals Rainbow Babies and Children’s Hospital and Case Western Reserve University, Cleveland, OH, ...
Positive full results from the NATRON Phase III trial showed AstraZeneca’s FASENRA(benralizumab) demonstrated a statistically significant delay in the time to first worsening or flare in ...
The MarketWatch News Department was not involved in the creation of this content. -- Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across ...
Statistics released late last month show that New Zealand’s richest households have expanded their wealth significantly, even as the country’s economy has gone into reverse and the majority of workers ...
UniQure has set its sights on submitting its Huntington’s disease gene therapy for approval next year after the asset was shown to slow progression of the neurodegenerative condition by 75% in a phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results